Published in Nat Rev Clin Oncol on October 19, 2010
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | NCT00429182
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer (2011) 2.19
The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med (2013) 2.18
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer (2011) 1.95
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther (2012) 1.44
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A (2014) 1.18
Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res (2012) 1.13
Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med (2011) 1.07
Extracellular vesicle profiling and their use as potential disease specific biomarker. Front Immunol (2014) 1.05
DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest (2014) 0.97
An automated high-throughput counting method for screening circulating tumor cells in peripheral blood. Anal Chem (2013) 0.96
Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol (2012) 0.95
Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med (2012) 0.94
Cytokeratin-based CTC counting unrelated to clinical follow up. J Thorac Dis (2013) 0.91
Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition. PLoS One (2012) 0.91
Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer (2012) 0.91
Circulating Tumor Cell Analyses in Patients With Esophageal Squamous Cell Carcinoma Using Epithelial Marker-Dependent and -Independent Approaches. Medicine (Baltimore) (2015) 0.89
Translating metastasis-related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol (2013) 0.88
Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res (2014) 0.87
Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis. Chin J Cancer (2011) 0.87
Pyruvate Carboxylase Is Up-Regulated in Breast Cancer and Essential to Support Growth and Invasion of MDA-MB-231 Cells. PLoS One (2015) 0.87
Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol Pharm (2013) 0.87
Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer (2014) 0.86
FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression. Neoplasia (2014) 0.84
Circulating tumor cells in breast cancer. J Carcinog (2014) 0.83
Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer. BMC Cancer (2015) 0.82
Ganoderiol A-enriched extract suppresses migration and adhesion of MDA-MB-231 cells by inhibiting FAK-SRC-paxillin cascade pathway. PLoS One (2013) 0.81
Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells. Sci Rep (2016) 0.80
The marine-derived sipholenol A-4-O-3',4'-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling. Mar Drugs (2014) 0.80
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer (2016) 0.80
Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging. Sci Rep (2015) 0.79
Role of RANKL/RANK in primary and secondary breast cancer. World J Orthop (2013) 0.79
Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomedicine (2014) 0.79
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget (2016) 0.78
Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells. Methods (2015) 0.78
Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis. Chin J Cancer (2017) 0.78
Current Approaches of Photothermal Therapy in Treating Cancer Metastasis with Nanotherapeutics. Theranostics (2016) 0.77
CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC Cancer (2016) 0.77
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis (2016) 0.77
Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients. Oncoimmunology (2015) 0.76
Analysis of DNA methylation in single circulating tumor cells. Oncogene (2017) 0.76
Progress in the research on the mechanism of bone metastasis in lung cancer. Mol Clin Oncol (2016) 0.75
Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget (2016) 0.75
Targeted Inhibition of Snail Activity in Breast Cancer Cells by Using a Co(III) -Ebox Conjugate. Chembiochem (2015) 0.75
Characterization of DNA Methylation in Circulating Tumor Cells. Genes (Basel) (2015) 0.75
Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells. Cancer Cell Int (2017) 0.75
Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods. Dis Markers (2017) 0.75
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. Int J Mol Sci (2016) 0.75
MicroRNA-200b Impacts Breast Cancer Cell Migration and Invasion by Regulating Ezrin-Radixin-Moesin. Med Sci Monit (2016) 0.75
53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer. Cancer Sci (2015) 0.75
Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. Onco Targets Ther (2017) 0.75
Suppression of CUL4A attenuates TGF-β1-induced epithelial-to-mesenchymal transition in breast cancer cells. Int J Mol Med (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Molecular portraits of human breast tumours. Nature (2000) 94.14
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol (2003) 11.12
Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol (2009) 9.87
An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) (1995) 9.18
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Systemic spread is an early step in breast cancer. Cancer Cell (2008) 7.91
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Plasticity of cell migration: a multiscale tuning model. J Cell Biol (2009) 5.82
Seeding and propagation of untransformed mouse mammary cells in the lung. Science (2008) 5.33
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol (2007) 5.21
Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst (1970) 4.88
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res (2009) 3.76
Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol (2008) 3.64
Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol (2009) 3.36
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A (2009) 3.19
Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res (2006) 3.12
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood (2000) 2.78
Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res (2009) 2.68
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia (2009) 2.60
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol (2009) 2.52
Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res (1975) 2.49
Mechanisms of motility in metastasizing cells. Mol Cancer Res (2010) 2.42
High speed detection of circulating tumor cells. Biosens Bioelectron (2006) 2.29
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Plasminogen activation and cancer. Thromb Haemost (2005) 2.21
Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res (2008) 2.19
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res (2008) 2.16
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res (2003) 1.94
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol (2010) 1.91
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat (2009) 1.86
Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res (2005) 1.84
Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci U S A (2009) 1.84
Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol (2010) 1.80
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res (2009) 1.78
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res (2007) 1.78
Apoptosis: an early event in metastatic inefficiency. Cancer Res (2001) 1.74
Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia (2010) 1.73
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol (2009) 1.71
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol (2007) 1.69
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res (2008) 1.67
CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res (2005) 1.66
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer (2008) 1.63
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A (2006) 1.61
Tumor progression: Small GTPases and loss of cell-cell adhesion. Bioessays (2003) 1.58
Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer (2009) 1.55
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol (2009) 1.51
Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell (2005) 1.51
Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J Cell Sci (2004) 1.50
Migration rules: tumours are conglomerates of self-metastases. Br J Cancer (2009) 1.48
Prognostic and predictive factors revisited. Breast (2005) 1.39
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res (2008) 1.37
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer (2009) 1.30
Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Res (2008) 1.29
Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer (2010) 1.20
Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev (2007) 1.20
Signalling mechanisms of anoikis. Histol Histopathol (2004) 1.20
Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res (2009) 1.16
A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res (2003) 1.16
Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost (2008) 1.10
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res (2002) 1.07
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer (2004) 1.00
Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost (2007) 0.99
Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer (2008) 0.98
Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods (2005) 0.97
Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics (2009) 0.94
Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer (2009) 0.93
Warfarin for cancer prevention. N Engl J Med (2000) 0.91
Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J (2010) 0.89
Cancer stem cells, self-seeding, and decremented exponential growth: theoretical and clinical implications. Breast Dis (2008) 0.89
New insights into the pathogenesis of breast cancer metastasis. Breast Dis (2007) 0.79
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res (2008) 7.91
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Exploring a new twist on tumor metastasis. Cancer Res (2006) 3.96
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res (2007) 3.04
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia (2009) 2.60
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells (2010) 2.54
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin (2010) 2.45
Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.38
Inflammatory breast cancer: what progress have we made? Oncology (Williston Park) (2011) 2.25
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology (2008) 2.05
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer (2010) 2.00
Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res (2011) 1.96
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res (2003) 1.94
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell (2013) 1.93
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer (2010) 1.90
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res (2013) 1.76
Trends for inflammatory breast cancer: is survival improving? Oncologist (2007) 1.70
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res (2005) 1.64
Breast cancer metastasis: challenges and opportunities. Cancer Res (2009) 1.63
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer (2008) 1.63
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol (2010) 1.63
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest (2012) 1.53
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol (2004) 1.52
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol (2009) 1.51
Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res (2008) 1.49
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48
Is Personalized Medicine Here? Oncology (Williston Park) (2016) 1.47
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther (2012) 1.44
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer (2011) 1.39
Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer (2007) 1.38
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer (2010) 1.37
Dyadic coping in metastatic breast cancer. Health Psychol (2010) 1.36
Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med (2012) 1.35
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res (2008) 1.33
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol (2005) 1.33
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat (2007) 1.31
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res (2013) 1.30
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med (2009) 1.29
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat (2008) 1.28
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist (2011) 1.22
Cancer stem cells: implications for cancer therapy. Oncology (Williston Park) (2014) 1.21
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat (2010) 1.19
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res (2005) 1.19
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. Eur J Cancer (2011) 1.19
Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol (2009) 1.19
Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A (2014) 1.18
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys (2008) 1.15
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer (2011) 1.14
Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol (2002) 1.13
Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci Rep (2013) 1.13
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res (2005) 1.12
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer (2004) 1.11
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 1.11
Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol (2011) 1.11
Nanotechnology for breast cancer therapy. Biomed Microdevices (2009) 1.10
Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol (2003) 1.08
Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat (2013) 1.08
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol (2009) 1.07
Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med (2011) 1.07
Inflammatory breast cancer. Semin Radiat Oncol (2009) 1.06
CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist (2009) 1.05
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int J Cancer (2010) 1.05
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat (2011) 1.05
The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer (2011) 1.04
Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 1.04
Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res (2012) 1.03
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol (2005) 1.03
A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17. J Proteome Res (2012) 1.03
Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Cytometry A (2014) 1.02
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res (2003) 1.02
Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. PLoS One (2013) 1.01
Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients. Breast J (2015) 1.00
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol (2010) 0.99
Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol (2008) 0.99
What progress have we made in managing inflammatory breast cancer? Oncology (Williston Park) (2007) 0.99
Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT. Eur J Nucl Med Mol Imaging (2009) 0.98